Search results
Results from the WOW.Com Content Network
well-differentiated neuroendocrine tumors, further subdivided into tumors with benign and those with uncertain behavior; well-differentiated (low grade) neuroendocrine carcinomas with low-grade malignant behavior; poorly differentiated (high grade) neuroendocrine carcinomas, which are the large cell neuroendocrine and small cell carcinomas.
The new 2019 WHO classification and grading criteria for neuroendocrine tumors of the digestive system grades all the neuroendocrine tumors into three grades, based on their degree of cellular differentiation (from well-differentiated NET grade (G)1 to G3, and poorly-differentiated neuroendokrina cancer, NEC G3), morphology, mitotic rate and Ki ...
The immunohistochemical phenotype of focal neuroendocrine differentiation in prostate cancer has been intensively studied. Chromogranin A, which is the most abundant product of prostatic neuroendocrine cells and neuroendocrine tumor cells, is widely recognized as a reliable marker for neuroendocrine differentiation. [4]
It is standardized with the C section of ICD-10. There were no changes in the topography axis between ICD-O-2 and ICD-O-3. See List of ICD-10 codes#(C00–C97) Malignant Neoplasms for examples.
The pathological definition published by the World Health Organization is “a generalized proliferation of scattered single cells, small nodules (neuroendocrine bodies), or linear proliferations of pulmonary neuroendocrine (PNE) cells that may be confined to the bronchial and bronchiolar epithelium.” [1] The true prevalence of this disease ...
[10] In 2000, the World Health Organization redefined "carcinoid", but this new definition has not been accepted by all practitioners. [11] This has led to some complexity in distinguishing between carcinoid and other neuroendocrine tumors in the literature. According to the American Cancer Society, the 2000 WHO definition states: [11]
The European Commission approved lutetium (177 Lu) oxodotreotide (brand name Lutathera) "for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults" in September 2017. [14] [4]
Thyroglobulin can be used as a tumor marker for well-differentiated papillary thyroid cancer. [7] [8] HBME-1 staining may be useful for differentiating papillary carcinomas from follicular carcinomas; in papillary lesions it tends to be positive.